Biotech Values

[bladerunner1717]

re: GLYC

Biotech Jim,

This may be a bit of a quibble, but the CMO seems to be qualified for the development of Rivipansel. Now that Pfizer has taken over development, she seems a bit under-qualified for a cancer drug development company. I'd prefer to see someone in that position (an MD) with more experience in cancer drug development. As GLYC's cancer drugs enter late-stage trials, this is more of an issue, IMHO.


Bladerunner